Announcements
Sidley Represents BioRender in Investment Valuing Company at $900 Million
January 2, 2026
Sidley represented BioRender, a scientific communication platform with the mission of accelerating the world’s ability to learn, discover, and communicate science, in connection with a strategic investment from Dimension Capital that values the company at approximately $900 million. As part of the transaction, BioRender provided liquidity to its employees.
The Sidley team was led by Michael Podolny (Emerging Companies and Venture Capital), and included Chloe Kaufman and Celine Gruaz (Emerging Companies and Venture Capital); Nicholas Frey (Employee Benefits and Executive Compensation); and Jonathan Westreich (Tax).
Contacts
Capabilities
Suggested News & Insights
2026 Emerging Companies & Venture Capital SummitWednesday, May 20, 2026Chambers Global Practice Guides – Corporate M&A 2026April 24, 2026Sidley Represents Valius Sciences in Financing Raising More Than US$10 Million for Future Cancer DiagnosticsApril 23, 2026New U.S. SEC Exemptive Order on Tender Offers Will Meaningfully Streamline Certain Liquidity TransactionsApril 21, 2026Sidley Represents Galera Therapeutics in Its Merger With Obsidian Therapeutics and US$350 Million Private Placement FinancingApril 21, 2026Sidley Represents Neomorph in Its US$100 Million Series B FinancingApril 15, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory



